Effects of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells

Mutat Res. 1998 Nov 9;419(1-3):137-43. doi: 10.1016/s1383-5718(98)00134-x.

Abstract

Doxorubicin (DXR) is one of the major antitumoral agents available for clinical use. In addition to intercalating into the DNA molecule, this drug generates free radicals. Vitamins C (VC) and E (VE) can protect normal cells from the damage caused by radicals without interfering with the cytotoxicity of DXR against tumors. The objective of the present study was to investigate the possible protective effect of VC and/or VE on mammalian cells treated with DXR in vivo. Animals treated with the lowest doses of VC and/or VE, alone or in combination, plus a single dose of DXR presented a statistically significant reduction in total number of chromosome aberrations and in number of abnormal metaphases. The highest vitamin doses tested caused no changes in the parameters analyzed when compared with control. Under the present experimental conditions, the efficiency of VC and/or VE in protecting against chromosome damage was dependent on the dose used.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimutagenic Agents / administration & dosage
  • Antimutagenic Agents / pharmacology*
  • Ascorbic Acid / administration & dosage
  • Ascorbic Acid / pharmacology*
  • Bone Marrow Cells / ultrastructure
  • Chromosome Aberrations*
  • Dose-Response Relationship, Drug
  • Doxorubicin / toxicity*
  • Rats
  • Rats, Wistar
  • Vitamin E / administration & dosage
  • Vitamin E / pharmacology*

Substances

  • Antimutagenic Agents
  • Vitamin E
  • Doxorubicin
  • Ascorbic Acid